Apimeds Restructures Board and Appoints New Director
I'm LongbridgeAI, I can summarize articles.Apimeds Pharmaceuticals US, Inc. announced a board restructuring and the appointment of Co-CEO Sungjoon Chae as a director on September 10, 2026. This follows an amendment to a settlement agreement, limiting the board to four directors initially before expanding to seven. The move reinforces Inscobee’s governance presence while maintaining independence standards.
Apimeds Pharmaceuticals US, Inc. ( (APUS) ) has provided an announcement.
On September 10, 2026, Apimeds Pharmaceuticals US, Inc. and its affiliated parties executed a first amendment to their April 24, 2026 confidential settlement and mutual release agreement, restructuring the composition of the company’s board of directors. During the interim period before preferred stock conversion, the board will be limited to four named directors who cannot be removed without the consent of major stakeholders, after which it will expand to seven members with seats allocated among MindWave-nominated independent directors, nominees of Dr. Vin Menon, and Inscobee’s representative.
The same day, the board appointed Co-Chief Executive Officer Sungjoon Chae as a director pursuant to the Inscobee parties’ nomination, with no related-party, family, or special selection arrangements reported. His compensation as a director has yet to be determined, and his appointment reinforces Inscobee’s governance presence while maintaining formal independence standards that are likely to shape the company’s strategic oversight and stakeholder balance going forward.
More about Apimeds Pharmaceuticals US, Inc.
Apimeds Pharmaceuticals US, Inc., a Delaware-based life sciences company, operates through subsidiaries including MindWave Innovations and maintains strategic ties with South Korean entities FreeT Inc. and Apimeds Inc. The group’s structure reflects a cross-border focus that blends U.S. corporate governance with Korean ownership interests, positioning the firm within a complex international stakeholder framework.
The company’s leadership includes Co-Chief Executive Officer Sungjoon Chae, appointed in May 2026, whose background in architecture and large-scale urban development emphasizes practical execution, financial viability, and stakeholder coordination. His experience managing multidisciplinary teams across South Korea and the United States underlines an operational emphasis on aligning strategy, design, and long-term asset value within regulated markets.
Average Trading Volume: 73,869
Technical Sentiment Signal: Sell
Current Market Cap: $3.46M
Learn more about APUS stock on TipRanks’ Stock Analysis page.